brand logo

Am Fam Physician. 2017;96(2):87-96

Related letter: Ketogenic Diet an Option for Treating Uncontrolled Epilepsy

Patient information: See related handout on seizures and epilepsy.

Author disclosure: No relevant financial affiliations.

The occurrence of a single seizure does not always require initiation of antiepileptic drugs. Risk of recurrent seizures should guide their use. In adults, key risk factors for recurrence are two unprovoked seizures occurring more than 24 hours apart, epileptiform abnormalities on electroencephalography, abnormal brain imaging, nocturnal seizures, or an epileptic syndrome associated with seizures. In children, key risk factors are abnormal electroencephalography results, an epileptic syndrome associated with seizures, severe head trauma, and cerebral palsy. The risk of adverse effects from antiepileptic drugs is considerable and includes potential cognitive and behavioral effects. In the absence of risk factors, and because many patients do not experience recurrence of a seizure, physicians should consider delaying use of antiepileptic drugs until a second seizure occurs. Delaying therapy until a second seizure does not affect one- to two-year remission rates. Treatment should begin with monotherapy. The appropriate choice of medication varies depending on seizure type. Routine monitoring of drug levels is not correlated with reduction in adverse effects or improvement in effectiveness and is not recommended. When patients have been seizure free for two to five years, discontinuation of antiepileptic drugs may be considered. For patients with seizures that are not controlled with these agents, alternative treatments include surgical resection of the seizure focus, ketogenic diets, vagus nerve stimulators, and implantable brain neurostimulators. Patients who have had a recent seizure within the past three months or whose seizures are poorly controlled should refrain from driving and certain high-risk physical activities. Patients planning for pregnancy should know that antiepileptic drugs are possibly teratogenic.

The lifetime risk of developing epilepsy is 3.9%, with males having a slightly higher risk.1 However, because many persons (particularly children) become seizure free, at any given time epilepsy affects less than 1% of the U.S. population, with a disproportionate impact on infants and older adults.2 Total annual health care costs associated with epilepsy are an estimated $15.5 billion.3 Illness-related absences from work or school occur more commonly in patients with epilepsy, further increasing the economic burden.4

Clinical recommendationEvidence ratingReferences
Electroencephalography should be used to confirm, but not to exclude, a diagnosis of epilepsy.B12, 13
Children should not routinely be started on an AED to prevent recurrent seizures after a first unprovoked seizure. The use of AEDs should be considered only when the benefits of reducing the risk of a second seizure outweigh the risks of an adverse drug effect.B19
Monotherapy with all indicated AEDs should be attempted before initiating combination therapy.B8, 10, 24
Routine monitoring of AED levels is not recommended unless clinically indicated.B13, 26, 27
Women of childbearing age should be counseled about the potential decreased effectiveness of AEDs when used with estrogen-based contraception, teratogenicity of AEDs, adverse neurodevelopmental outcomes, and increase in risk of complications during pregnancy and labor; and they should be offered genetic counseling.C8, 4750
Screening for cognitive difficulties and mental health issues is recommended at diagnosis because of the high prevalence of cognitive impairment and mood disorders among persons with epilepsy.C54

A single seizure may occur for a number of reasons and is not necessarily diagnostic of epilepsy.5 Although diagnosis of epilepsy requires the occurrence of at least one epileptic seizure, predisposing factors to recurrent seizures must also be present.5

Seizures are typically characterized as generalized (tonic-clonic, involving both hemispheres and multiple structures) or focal. Focal seizures are limited to one hemisphere and may be discretely localized or more widely distributed. Further seizure classification can be found in Table 1.611

First-line monotherapy based on level of evidence*
Seizure classification with definition and characteristicsChildren (younger than 16 years)Adults
Focal (partial)Level A: oxcarbazepine (Trileptal)Younger adults (16 to 59 years of age)
Seizure originating within networks limited to one hemisphere characterized by subjective (aura), motor, autonomic, and dyscognitive featuresLevel B: noneLevel A: carbamazepine, levetiracetam (Keppra), phenytoin, zonisamide
Level C: carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), topiramate (Topamax), valproic acid (Depakene), vigabatrin (Sabril)Level B: valproic acid
Level D: clobazam (Onfi), clonazepam (Klonopin), lamotrigine (Lamictal), zonisamide (Zonegran)Level C: gabapentin (Neurontin), lamotrigine, oxcarbazepine, phenobarbital, topiramate, vigabatrin
Level D: clonazepam, primidone (Mysoline)
Older adults (60 years and older)
Level A: gabapentin, lamotrigine
Level B: none
Level C: carbamazepine
Level D: topiramate, valproic acid
Generalized
ConvulsiveLevel A: noneLevel A: none
Typically bilateral and symmetric, although variants with asymmetry, including head and eye deviation, are possibleLevel B: noneLevel B: none
AtonicLevel C: carbamazepine, phenobarbital, phenytoin, topiramate, valproic acidLevel C: carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid
Loss or diminution of muscle tone without apparent preceding myoclonic or tonic featuresLevel D: oxcarbazepineLevel D: gabapentin, levetiracetam, vigabatrin
Very brief (less than two seconds) and may involve the head, trunk, or limbs
Tonic
Bilaterally increased tone of the limbs typically lasting seconds to one minute
Often occur while awake and in sequences of varying intensity of tonic stiffening
MyoclonicLevel A: noneLevel A: none
Level of awareness varies, ranging from complete loss of awareness to retained awarenessLevel B: noneLevel B: none
Rhythmic myoclonic jerks of the shoulders and arms with tonic abduction that results in progressive lifting of the arms during the seizure are typicalLevel C: noneLevel C: carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid
Can be bilateral, unilateral, or asymmetricLevel D: topiramate, valproic acidLevel D: gabapentin, levetiracetam, vigabatrin
Perioral myoclonia and rhythmic jerks of the head and legs may occur; seizures last 10 to 60 seconds and typically occur daily
Myoclonic status epilepticus is characterized by ongoing (more than 30 minutes) irregular jerking, often with partially retained awareness
Negative myoclonic
Background muscle tone undergoes brief cessation lasting less than 500 milliseconds
May have an initial loss of posture caused by negative myoclonus, followed by subsequent voluntary and compensatory movement to restore posture
Myoclonic-atonic
Myoclonic seizure occurs, followed by an atonic seizure
A series of myoclonic jerks may occur before atonia and may be hard to detect
Patients typically experience a sudden fall because the seizure affects the head and limbs
AbsenceLevel A: ethosuximide (Zarontin), valproic acidLevel A: none
TypicalLevel B: noneLevel B: none
Onset and offset of altered awareness occurs abruptly, myoclonus of limbs is rare, and oral and manual automatisms are commonLevel C: lamotrigineLevel C: carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid
Severity can vary; clonic movements of facial parts may occurLevel D: noneLevel D: gabapentin, levetiracetam, vigabatrin
Behaviors before seizure onset may extend repeatedly
Atypical
Onset and offset of loss of awareness is less than abrupt
Often associated with other features, such as loss of muscle tone of the head, trunk, or limbs, and subtle myoclonic jerks
Eyelid myoclonia
Awareness is retained
Absence seizures are associated with brief, repetitive, and often rhythmic, fast (4 to 6 Hz) myoclonic jerks of the eyelids with simultaneous upward deviation of the eyeballs and extension of the head
Typically very brief (less than six seconds in duration) and occur multiple times daily
Myoclonic absence
Causes rhythmic myoclonic jerks of the shoulders and arms and results in progressive lifting of the arms during the seizure due to tonic abduction
Myoclonic jerks are typically bilateral, but may be unilateral or asymmetric
Perioral myoclonia and rhythmic jerks of the head and legs may occur
Seizures last 10 to 60 seconds and typically occur daily
Level of awareness during seizure varies
Focal/generalizedOptimal treatment not well defined and patients should be treated based on whether seizure activity is focal or generalized using the drugs listed above
Epileptic spasms
May be focal or generalized
Sudden flexion, extension, or mixed flexion-extension of proximal and truncal muscles lasting longer than a myoclonic jerk (which lasts milliseconds) but not as long as a tonic seizure (which lasts more than two seconds)
Occur in a series, usually on wakening
Subtle forms may occur with only chin movement, grimacing, or head nodding
May be bilaterally symmetric, asymmetric, or unilateral

Diagnostic Evaluation

Diagnosis of epilepsy is dependent on history, physical and neurologic examination, laboratory testing as indicated, and electroencephalography and neuroimaging findings. The history should include events directly preceding the seizure, number of seizures in the past 24 hours, length and description of the seizure, focal aspects, and length of the postictal period. The need for laboratory testing is based on clinical context and may include blood glucose, blood counts, electrolyte panels (particularly sodium), lumbar puncture in febrile patients, and urine toxicology (Figure 1). Electroencephalography should be used to confirm, but not to exclude, a diagnosis of epilepsy.12,13 Evaluation of a patient who has experienced a first seizure has previously been reviewed, including in American Family Physician.1214

Decision to Begin Treatment

The occurrence of a single seizure does not always require initiation of antiepileptic drug (AED) therapy, and the decision to initiate long-term therapy should be made in consultation with a physician who specializes in seizure management. Referral for any unexplained initial seizure, especially when high-risk characteristics are identified or multiple seizures occur, is reasonable to help determine the risk of recurrence and the risks and benefits of treatment as opposed to watchful waiting.8,15

ADULTS AT HIGH RISK OF RECURRENCE

Adults at high risk of recurrent seizures should receive AED therapy. High-risk characteristics include two unprovoked seizures occurring more than 24 hours apart; one unprovoked seizure and an assessment that predicts an increased probability of further seizures based on underlying cause and seizure characteristics; or a diagnosis of an epilepsy syndrome in which recurrent seizures are a prominent feature (http://www.epilepsy.com/learn/types-epilepsy-syndromes). Epileptiform abnormalities on electroencephalography also predict a high risk of recurrence (60% over 10 years), as does abnormal brain imaging or a nocturnal seizure.810,1518 Adults should be counseled that the cumulative risk of a recurrent seizure after a first unprovoked seizure is approximately 50% over five years, with one-third of the risk accruing in the first year. In persons 65 years and older, the risk of recurrence following a first unprovoked seizure is 53% within one year (lifetime risk is 80%).16 Initiating AED therapy after the first seizure decreases the absolute risk of recurrence by 35% over the next two years. AED therapy is almost always indicated after two unprovoked seizures occurring more than 24 hours apart because of the high recurrence rate (32% at three months, 57% at one year, 73% at four years). AEDs may not improve quality of life and prognosis for sustained seizure remission. The risk of an adverse effect from an AED ranges from 7% to 31%.1618

ADULTS AT LOW RISK OF RECURRENCE

In adults who have had a single seizure and who lack high-risk characteristics, delaying AED therapy until a second seizure does not affect one- to two-year seizure remission rates. AEDs are associated with significant adverse effects, including subtle cognitive and behavioral effects occurring in up to 50% of treated patients; therefore, delaying their use until a second seizure is reasonable.16

CHILDREN

With the exception of children with febrile seizures, the risk of a recurrent seizure after a first unprovoked seizure is more than 20% in the first year and more than 50% at 10 years. One in five children who have had a nonfebrile seizure will have four or more seizures, and one in 10 will have 10 or more seizures.19 Predictors of recurrence include abnormal electroencephalography results, the presence of a syndrome predisposing to seizures, and an etiology such as severe head trauma or cerebral palsy.

In the absence of such risk factors, there is generally no difference in one- to two-year seizure remission rates between starting AED therapy after the first childhood seizure and starting it after a second seizure. Additionally, the risk of an adverse effect associated with treatment is considerable—as high as 50% in some studies—and includes subtle cognitive and behavioral effects.19 In the absence of relevant risk factors, AED therapy is not indicated after a first unprovoked childhood seizure. Such treatment is reasonable, however, in children with relevant risk factors if the benefits of reducing the risk of a second seizure are thought to outweigh the risks of an adverse effect.19

SUDDEN UNEXPECTED DEATH IN EPILEPSY

Early initiation of AED therapy may reduce the risk of sudden unexpected death in epilepsy (SUDEP), which is death in a person with epilepsy in whom no other cause of death is found. A significant risk factor for SUDEP is nocturnal seizures. Although rare in children, SUDEP is the leading cause of epilepsy-related death among young adults with uncontrolled epilepsy, occurring in nine per 1,000 persons with epilepsy overall, but as many as one in 150 persons with poor seizure control.20,21 The risk of SUDEP can be decreased by optimizing seizure control.22,23

Pharmacotherapy

DRUG SELECTION

Choice of AED should be individualized in consultation with a neurologist, and based on factors such as seizure type, presence of an epilepsy syndrome, other medications, comorbidities, lifestyle, and patient preference. Quality of evidence and treatment recommendations vary among seizure types (Table 1611 ).

Monotherapy with all indicated AEDs should be attempted before initiating combination therapy.8,10,24 Although each AED has its own unique adverse effect profile, effects on the central nervous system are prominent and can affect quality of life (Table 2).10,13,24,25

Antiepileptic drugInitial dosageMaximum dosage (may not be required for all patients)Titration and administrationContraindicationsAdverse effects
Carbamazepine (Tegretol)400 mg daily2,400 mg dailyGiven two to four times dailyBone marrow suppression; sensitivity to tricyclic compoundsAbnormal coordination, ataxia, blood dyscrasias, constipation, dizziness, headache, hyponatremia, metabolic bone disease, nausea, nystagmus, rash (human leukocyte antigen testing may be relevant), somnolence, vomiting
Increase dosage every two to three weeks until response is reached
Target serum concentration: 4 to 12 mcg per mL
Clobazam (Onfi)Patient weighs 30 kg (66 lb) or less: 5 mg dailyPatient weighs 30 kg or less: 20 mg dailyPatient weighs 30 kg or less: increase to 10 mg on day 7, then to 20 mg on day 14No specific contraindicationsAggression, ataxia, constipation, increased salivation, insomnia, irritability, nausea, vomiting, somnolence
Patient weighs more than 30 kg: 10 mg dailyPatient weighs more than 30 kg: 40 mg dailyPatient weighs more than 30 kg: increase to 20 mg on day 7, then to 40 mg on day 14
Clonazepam (Klonopin)Children: 0.05 mg per kg dailyChildren: 0.1 to 0.2 mg per kg dailyGiven in three divided dosesSignificant liver disease, acute narrow angle glaucomaAnorexia, ataxia, behavioral problems, constipation, dizziness, drowsiness
Children: increase by 0.25 to 0.5 mg every three days to maintenance dosage of 0.1 to 0.2 mg per kg daily
Adults: 1.5 mg dailyAdults: 20 mg dailyAdults: Increase by 0.5 to 1 mg every three days until response is reached
Ethosuximide (Zarontin)500 mg daily2,000 mg dailyTypically given once dailyHypersensitivity to succinimidesBehavioral changes, blood dyscrasias, drowsiness, hyperactivity, nausea, rash, sleep disturbance, vomiting
Titrate over one to two weeks to maintenance dosage of 20 mg per kg daily
Target serum concentration: 40 to 100 mcg per mL
Gabapentin (Neurontin)Three to 12 years of age: 10 to 15 mg per kg dailyThree to 12 years of age: 40 mg per kg dailyGiven in three divided dosesNo specific contraindicationsAtaxia, dizziness, somnolence
Older than 12 years: 300 to 900 mg dailyOlder than 12 years: 1,800 mg dailyTitrate to effective dosage over approximately three days
Lamotrigine (Lamictal)Specific dosing recommendations depend on other current antiepileptic drugsSpecific dosing recommendations depend on other current antiepileptic drugsSpecific dosing recommendations depend on other current antiepileptic drugsNo specific contraindicationsDiplopia, dizziness, nausea, rash, tremor
Levetiracetam (Keppra)500 to 1,000 mg daily4,000 mg dailyGiven in two divided doses, increase every two weeksNo specific contraindicationsAgitation, anxiety, depression, dizziness, fatigue, infection, irritability, rash, somnolence,
Target serum concentration: 12 to 46 mcg per mL
Oxcarbazepine (Trileptal)Four to 16 years of age: 8 to 10 mg per kg dailyFour to 16 years of age: weight basedGiven in two divided dosesNo specific contraindicationsAtaxia, diplopia, dizziness, headache, hyponatremia, nausea, rash, sedation, vertigo
Older than 16 years: 600 mg dailyOlder than 16 years: 1,200 mg dailyFour to 16 years of age: increase by 5 mg per kg daily every three days to recommended dosing
Older than 16 years: 300 mg every three days to maximum
PhenobarbitalChildren: 30 mg dailyChildren: 150 mg dailyGiven in two to three divided dosesAcute intermittent porphyria, marked impairment of liver function, respiratory disease, known previous addiction to sedative/hypnotic drugsAgitation, anxiety, ataxia, confusion, constipation, dizziness, drowsiness, hallucinations, hyperkinesia, impaired judgment, insomnia, lethargy, nausea, vomiting
Adults: 200 to 300 mg dailyAdults: 300 mg daily
Phenytoin (Dilantin)3 to 5 mg per kg (200 to 400 mg) daily600 mg dailyGiven in four equal doses, six hours apartHypersensitivity to hydantoinsAtaxia, blood dyscrasias, confusion, double vision, gingival hypertrophy, immunologic reaction, rash (human leukocyte antigen testing may be relevant), slurred speech
Total serum concentration: 10 to 20 mcg per mL
Unbound drug concentration: 0.5 to 3 mcg per mL
Primidone (Mysoline)100 to 125 mg daily750 mg dailyDays 1 through 3: 100 to 125 mg at bedtimeHypersensitivity to phenobarbital; porphyriaAlteration of sleep cycles, ataxia, behavioral changes, hyperactivity, lethargy, nausea, rash, sedation
Days 4 through 6: 100 to 125 mg two times daily
Days 7 through 9: 100 to 125 mg three times daily
Day 10 onwards: 250 mg three times daily
Topiramate (Topamax)50 mg daily400 mg dailyWeek 1: 25 mg two times dailyNo specific contraindicationsConfusion, depression, difficulty concentrating, fatigue, language problems, nervousness, paresthesias, tremor, weight loss
Week 2: 50 mg two times daily
Week 3: 75 mg two times daily
Week 4: 100 mg two times daily
Week 5: 150 mg two times daily
Week 6: 200 mg two times daily
Valproic acid (Depakene)15 mg per kg (500 to 1,000 mg) daily60 mg per kg (3,000 to 5,000 mg) dailyGiven once or twice daily, typically twice dailyLiver disease or impaired liver functionAlopecia, dizziness, hyperammonemia, polycystic ovary syndrome, tremor, weight gain
Target serum concentration: 50 to 100 mcg per mL
Vigabatrin (Sabril)50 mg per kg daily150 mg per kg dailyGiven twice daily and titrated up by 25 to 50 mg per kg daily every three daysNo specific contraindicationsDizziness, drowsiness, fatigue, vision loss
Zonisamide (Zonegran)100 to 200 mg daily400 to 600 mg dailyGiven once or twice daily and increased every two weeksHypersensitivity to sulfonamidesAcidosis, metabolic nephrolithiasis, oligohydrosis, rash
Target serum concentration: 10 to 40 mcg per mL

MONITORING ANTIEPILEPTIC DRUG LEVELS

Routine monitoring of AED levels does not reduce adverse effects or improve effectiveness and is not recommended. Clinical indications for monitoring AED levels include establishment of individual therapeutic concentrations when desired clinical outcomes have been reached, diagnosing clinical toxicity, assessing compliance, and guiding dosage adjustment in situations with increased pharmacokinetic variability (e.g., in children or in patients who are very old, when drug formulation changes occur, during pregnancy).13,26,27

TREATMENT GOALS

Treatment goals, medication adherence, and adverse effects of AEDs should be reviewed at least annually with attention to seizure frequency, medication effects, preconception counseling, if indicated, and the need for referral to specialized centers for persistent symptoms.28 Discontinuation of AEDs can be considered in children with focal seizures once they have been seizure free for two years on monotherapy, and for children with all other seizure types after they have been seizure free for five years on monotherapy. Plans for discontinuation should be developed and executed in consultation with a neurologist.13,29

Surgical Intervention

Up to 30% of patients with epilepsy can have medically refractory epilepsy. These patients have continued seizures despite appropriate AED therapy.30 Surgical resection of the seizure focus in appropriately selected patients often results in decreased frequency or elimination of seizures with improvement in quality of life. Seizure freedom is achieved in up to 76% of patients after resection.31

Factors associated with seizure freedom after surgery include seizures without loss of consciousness, complete or extensive resection of the lesion, and prolonged febrile seizures. The possibility of recurrence decreases with increasing postoperative seizure-free intervals. Factors associated with postoperative recurrence include nonlesional (non-structural) epilepsy, normal magnetic resonance imaging, preoperative generalized tonic-clonic seizures, and infantile spasms or tonic seizures. Also, the need for invasive intracranial electroencephalography monitoring to determine seizure focus predicts a worse outcome.31

Cognitive deficits are common following surgery and depend on the site of the resection. Left temporal lobe resection is associated with verbal memory deficits (44%) and naming deficits (34%). After a right temporal lobe resection, verbal memory deficits are also common (20%). Operative mortality in most centers is below 0.5%. Lower mortality is associated with procedures limited to the temporal lobe. Other adverse effects include neurologic deficits (5%), medical complications (e.g., intracerebral infection, hydrocephalus; 1.5%), cerebrospinal fluid leak (8.5%), aseptic meningitis (3.6%), and noncerebral bacterial infections (3%). Other medical problems such as hemorrhage, pneumonia, and deep venous thrombosis are uncommon (2.5%).13,21,32

Other Approaches to Treatment

Nonpharmacologic approaches may be useful adjuncts in patents with difficult-to-control seizures or who find medication difficult to tolerate. They require a team-based approach for implementation.

The ketogenic diet, a high-fat, low-carbohydrate, and low-protein diet, induces ketone body formation. Proponents claim a 10% seizure-free rate and seizure-reduction rates of up to 60%. Supporting evidence is of poor quality. The many adverse effects include gastrointestinal symptoms (vomiting, constipation, diarrhea, abdominal pain), metabolic abnormalities (hyperuricemia, hypocalcemia, hypomagnesemia, decreased amino acid levels, acidosis), renal calculi, and cardiac abnormalities (cardiomyopathy and prolonged QT interval).13,33,34

Vagus nerve stimulation may increase seizure-free time in patients with medically refractory epilepsy who are not candidates for surgery or in whom surgery has been ineffective. It is approved by the U.S. Food and Drug Administration for use in persons older than 12 years. In this procedure, a battery-powered vagus nerve stimulator is implanted with the leads around the left vagus nerve and attached to a programmable pacemaker. The exact mechanism of action is unclear but likely due to vagal afferent activity that suppresses the electrical circuits in the brain that lead to seizures.13,3538

Responsive neurostimulation is another approach to treating medically refractory partial-onset seizures. This recently approved system is different from the vagus nerve stimulator in that the leads are implanted directly into the seizure-onset zone, which may be cortical or subcortical. In response to abnormal electrical activity, the neurostimulator delivers electrical stimulation to the target seizure-onset zone. Adverse effects include implant site pain, implant site infection, headache, and dysesthesia.39,40

Complementary and alternative therapies such as acupuncture, traditional Chinese medicine, cannabinoids, melatonin, vitamin supplementation, and yoga have been investigated, but none have sufficient evidence.4147

Further Considerations

CONTRACEPTION AND PREGNANCY

Women of childbearing age should be counseled, in consultation with a neurologist, about the potential decrease in effectiveness of AEDs when using estrogen-based contraception and offered alternative contraceptive methods. The potential teratogenicity of AEDs, potential adverse neurodevelopmental outcomes, and the potential increased risk of complications during pregnancy and labor should also be discussed, and genetic counseling offered before conception.8,4750 The incidence of major birth defects among infants born to women receiving AED monotherapy is 4% to 7%, almost twice the rate observed in the general population.3,13,4851

SCREENING FOR COGNITIVE IMPAIRMENT

Self-management education increases adherence and reduces seizure frequency in patients who are capable of medication self-management.13,52,53 Cognitive impairment and mood disorders have a high prevalence in epilepsy; screening for these and other mental health issues is recommended at diagnosis.54

DRIVING

Patients should be counseled not to drive until they have been seizure free for at least three months.55,56 Most states mandate a seizure-free period (three to 12 months) before resuming driving; some require physicians to report the diagnosis or treatment of epilepsy to the licensing agency. A database of driving laws related to seizure disorders is available at http://www.epilepsy.com/driving-laws. Physicians should routinely check with their state licensing agency for accurate and current information.

PHYSICAL ACTIVITY

Patients with epilepsy should be encouraged to participate in physical activity and sports. Regular physical activity, in addition to providing cardiovascular and psychological benefits, may decrease seizure frequency.57 Patients may participate in most sports, including bicycling, contact sports, and swimming, assuming seizures are well controlled and supervision is available. High-risk sports where a seizure may result in severe injury or death, such as hang-gliding, scuba diving, and free climbing, are not recommended.58 Information about sports activities for children with epilepsy is available at http://www.epilepsy.com/learn/seizures-youth/about-kids/playing-sports-and-other-activities.

This article updates previous articles by Vélez, et al.59 ; Morrell60 ; Benbadis, et al.61 ; and Marks, et al.62

Data Sources: PubMed was searched using the MeSH function and the key phrase epilepsy treatment. Meta-analyses, randomized controlled trials, clinical trials, and reviews were included. Also searched were Essential Evidence Plus, the Cochrane Database of Systematic Reviews, the U.S. Preventive Services Task Force website, and recommendations from the International League Against Epilepsy and the American Academy of Neurology. Search dates: December 15, 2015, to November 1, 2016.

Continue Reading


More in AFP

Copyright © 2017 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See https://www.aafp.org/about/this-site/permissions.html for copyright questions and/or permission requests.